Categories: Wire Stories

Sapient Therapeutics Announce Positive Results From Phase 1 Part A Trial for Its Solid Dose Prescription CBD

LONDON & MELBOURNE, Australia–(BUSINESS WIRE)–Sapient Therapeutics Ltd (“Sapient Therapeutics”), a pioneering biopharmaceutical company specialising in neuroscience drug discovery and early clinical development, is pleased to announce the successful completion of its Phase 1 Part A comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.


The positive results of this Phase 1 Part A trial demonstrate the tolerability and bioavailability of Sapient Therapeutics lead asset, SAP021, in comparison to Epidiolex®. The trial met all pharmacokinetic requirements, marking a significant milestone in the development of SAP021. As a result, the Company has progressed this solid dose CBD candidate into Part B of the trial with full results expected in H1 2024.

Giles Moss, Chief Executive Officer of Sapient Therapeutics commented: “A solid dose formulation of CBD could provide additional clinical benefit to patients experiencing and suffering from serious neurological diseases. These initial results confirm the early potential of SAP021, are consistent with our best-case scenario at this stage and set us up well for continuation of this trial to a successful outcome”.

Sapient Therapeutics plans to utilise an U.S. Food and Drug Administration (FDA) expedited and de-risked 505(b)(2) regulatory pathway, with a view to making a solid dose CBD prescription medicine commercially available for US patients in late H2 2027.

For and on behalf of Sapient Therapeutics Ltd:

Sapient Therapeutics is a UK based biopharmaceutical company focused on neuroscience drug discovery and early clinical development. Our lead asset (SAP021) has commenced Phase 1 studies and will complete in 2024. Our leadership team is comprised of neuroscience and cannabinoid medicine veterans. Together we are utilising the experience gained in cannabinoid drug development to bring new prescription medicines to patients suffering from serious diseases.

STx PR001 Nov2023

Contacts

Giles Moss, CEO

gmoss@sapienttx.com

Alex

Alex is a writer and digital content enthusiast who enjoys covering technology, current trends, useful tips, and topics that matter to everyday readers. With a focus on clear, informative, and easy-to-understand content, Alex aims to provide readers with practical insights and interesting perspectives across a wide range of subjects.

Recent Posts

Rams vs Bills Showdown: What to Expect on Monday Night Football

Key takeaways:The Rams host the Bills at SoFi Stadium for Week 5 Monday Night Football.Performers…

28 minutes ago

Auto Drivers’ Fare Hike Protests and CPI Demands in Tamil Nadu: Latest Updates

Key takeaways:Auto drivers in Tamil Nadu plan a candlelight march to oppose a fare hike…

58 minutes ago

Raúl Fernández Shocks MotoGP with Indonesian Pole and Warm‑Up Lead Despite Hand Injury

Key takeaways:Raúl Fernández secured pole position at the 2026 Indonesian MotoGP, surprising many competitors.He led…

1 hour ago

RJ Mitte: Breaking Bad Star, Disability Advocate, and His Untimely Death at 34

Key takeaways:RJ Mitte, known for playing Walter White Jr. on <em>Breaking Bad</em>, died at 34.Both…

2 hours ago

Fred Vasseur’s Take on Hamilton’s Singapore GP Strategy Mistake

Key takeaways:Fred Vasseur labeled Lewis Hamilton’s Singapore GP strategy a mistake.Hamilton publicly apologised to Ferrari…

3 hours ago

Brewers vs Dodgers NLCS Game 1: Misiorowski Shines as Dodgers Falter

Key takeaways:Milwaukee Brewers won NLCS Game 1 on October 13, 2026.Brewers ace Jacob Misiorowski pitched…

3 hours ago